Clinical Trials Browser

Interventional × Carcinoma, Basal Cell × talimogene laherparepvec × Clear all

NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT03458117 2022-03-18

20139157 T-VEC

Phase 1 Completed

26 enrolled

DermatologicLymphoid

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous